Full-Time

Medical Science Liaison Senior Manager

Field Medical, Northwest

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

201-500 employees

Commercializes MC4R-targeted therapies for rare obesity

Compensation Overview

$135k - $215k/yr

+ Annual bonus + Restricted stock units

Seattle, WA, USA

Remote

Candidates must be based in Seattle or Portland and travel 50–75% of the time.

Bachelor's, PharmD, PhD, MD, Doctor of Osteopathic Medicine (DO)

Category
Growth & Marketing (1)

Get referred to Rhythm Pharmaceuticals

See people who can refer or advise you

Requirements
  • An advanced scientific or clinical degree such as PharmD, PhD, MD, or DO is strongly preferred; candidates with a Doctor of Nursing Practice degree and relevant clinical experience in obesity, endocrinology, genetics, or neurology will also be considered.
  • At least 6 years of experience within the pharmaceutical, biotechnology, healthcare, or related industry.
  • Understanding of healthcare systems, patient care pathways, and the evolving medical landscape within the assigned territory or region.
  • Working knowledge of applicable regulations, industry guidance, and ethical standards governing Medical Affairs activities, including Good Clinical Practice, International Council for Harmonisation guidance, the PhRMA Code, Office of Inspector General guidance, and company policies.
  • Ability to critically evaluate, interpret, and communicate complex clinical and scientific information to diverse audiences.
  • Ability to develop and maintain credible, trusted relationships with key opinion leaders, investigators, healthcare professionals, and other external stakeholders.
  • Ability to generate insights and think strategically, translating field observations into meaningful insights, implications, and actionable recommendations that inform medical strategy and organizational decision-making.
  • Ability to work effectively within a cross-functional matrix environment, providing medical expertise and fostering collaboration to achieve shared medical and organizational objectives.
  • Ability to navigate change and ambiguity and adjust priorities in response to evolving organizational and healthcare needs.
  • Strong communication, presentation, and facilitation skills, including experience leading scientific discussions, educational programs, and training sessions.
  • Organizational, project management, and territory planning skills.
  • Willingness and ability to travel frequently, travel 50–75% of the time, and maintain easy access to transportation and airports.
Responsibilities
  • Serve as a trusted scientific partner to key external experts by delivering timely, evidence-based, and impactful scientific exchange that advances understanding of the scientific and clinical value of the company’s research and therapies.
  • Develop and execute strategic engagement plans with key opinion leaders and healthcare professionals to support implementation of the medical strategy.
  • Gather and communicate actionable medical insights with clear implications and recommendations from key opinion leaders, healthcare professionals, and healthcare systems to inform medical strategy, evidence generation, and organizational decision-making.
  • Serve as a scientific peer-to-peer resource to disease experts and the broader medical community by providing timely, balanced, and evidence-based scientific and clinical information.
  • Identify and cultivate relationships with potential investigators and provide field-based medical support for clinical trials, registries, real-world evidence initiatives, and other research programs.
  • Collaborate cross-functionally to provide scientific expertise and contribute to medical, scientific, and strategic initiatives at local, regional, and national levels.
  • Identify opportunities to advance patient care through research collaborations, educational initiatives, care-pathway assessment, identification of scientific and educational gaps, and other scientific partnership opportunities within key accounts and institutions.
  • Interpret and effectively communicate complex scientific and clinical data to address the educational and research needs of healthcare professionals, investigators, and other stakeholders, ensuring alignment with Medical Communications and medical strategy.
  • Maintain effective and appropriate communication among internal stakeholders, including Medical Affairs colleagues and Medical Information, while complying with company, industry, legal, and regulatory requirements.
  • Respond to unsolicited requests for medical information in a timely, accurate, balanced, and compliant manner.
  • Contribute to North America Medical Affairs initiatives, congress activities, field medical training programs, and other strategic projects as needed.
Desired Qualifications
  • Experience in rare disease, obesity, endocrinology, neurology, genetics, pediatrics, or other specialty therapeutic areas.
Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

View

Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2008

Get referred to Rhythm Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 IMCIVREE revenue reached $71.3 million, up 47% year over year.
  • More than 400 acquired-HO start forms arrived by June 30, 2026, signaling strong demand.
  • Japan approved acquired-HO IMCIVREE in August 2026, with launch targeted before year-end.

What critics are saying

  • March 2026 Phase 3 genetic-obesity failure blocks label expansion beyond current narrow indications.
  • Rhythm depends heavily on IMCIVREE; any launch stumble in Japan hits 2026 growth.
  • Next-generation MC4R drugs still need proof; RM-718's 11-patient dataset leaves an existential gap.

What makes Rhythm Pharmaceuticals unique

  • IMCIVREE is first approved therapy for acquired hypothalamic obesity in the US, Europe, Japan.
  • Rhythm owns the MC4R obesity franchise, spanning setmelanotide, RM-718, and bivamelagon.
  • Rare-disease genetics and diagnostic algorithms create defensible physician relationships beyond pure commercial advertising.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Performance Bonus

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

8%

2 year growth

2%
Yahoo Finance
Aug 24th, 2026
Japan approves Imcivree for acquired hypothalamic obesity, launch expected by end of 2026

Rhythm Pharmaceuticals has received approval from Japan's Ministry of Health, Labour and Welfare for IMCIVREE (setmelanotide) to treat patients with acquired hypothalamic obesity (HO). This marks the first therapy approved in Japan for this condition. The approval was supported by the Phase 3 TRANSCEND trial involving 142 patients, including a Japanese cohort. The study met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm estimates 5,000 to 8,000 people are living with acquired HO in Japan. The company expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Acquired HO is characterised by accelerated weight gain following hypothalamic injury, often resulting from craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumours.

Yahoo Finance
Aug 17th, 2026
Rhythm Pharmaceuticals appoints Manher Joshi as chief medical officer

Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.

Associated Press
Aug 11th, 2026
Rhythm Pharmaceuticals' IMCIVREE receives UK approval for acquired hypothalamic obesity treatment

Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.

Yahoo Finance
Aug 4th, 2026
Rhythm Pharma's RM-718 cuts BMI 11.6% in brain tumour obesity patients

Rhythm Pharmaceuticals reported preliminary results showing its experimental weekly injectable drug RM-718 helped reduce body weight in patients with acquired hypothalamic obesity, a rare condition caused by brain damage from tumour surgery or treatment. The Boston-based company's shares rose 5% in premarket trading. Among 11 enrolled patients, seven who completed 16 weeks of treatment saw their body mass index fall by an average of 11.6%. The drug works by activating the MC4R brain receptor, which controls hunger and metabolism. Two patients discontinued treatment due to side effects including nausea and injection site problems. Rhythm also sells setmelanotide for the same condition under the brand name Imcivree. Separately, the company reported second-quarter revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.

Associated Press
Aug 4th, 2026
Rhythm Pharmaceuticals Q2 2026 revenue hits $71.3M as new HO treatment gains 400+ patients

Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE, marking a 19% sequential increase from the first quarter. The company received over 400 patient start forms for IMCIVREE's acquired hypothalamic obesity indication from approximately 300 prescribers as of 30 June 2026, following FDA approval in March. US revenue reached $51.0 million, representing 72% of product revenue and a 38% sequential increase, driven primarily by acquired hypothalamic obesity demand. The company reported preliminary Phase 2 data showing weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in acquired hypothalamic obesity patients after 16 weeks. Cash, cash equivalents, and short-term investments totalled approximately $330.9 million as of 30 June 2026. The company posted a net loss of $50.4 million for the quarter.